-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Management of Toxicities Associated with Targeted Therapies: When to Push Through and When to Stop

Program: Education Program
Session: Acute Myeloid Leukemia - So Many Treatment Options; How Do You Decide?
Hematology Disease Topics & Pathways:
Biological, Therapies, Adverse Events, Clinically relevant
Monday, December 7, 2020, 6:55 AM-7:00 AM

Eunice S. Wang, MD

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Disclosures: Wang: Astellas: Consultancy; Genentech: Consultancy; Pfizer: Speakers Bureau; Abbvie: Consultancy; Jazz Pharmaceuticals: Consultancy; Macrogenics: Consultancy; PTC Therapeutics: Consultancy; Stemline: Speakers Bureau; Bristol Meyers Squibb (Celgene): Consultancy.

OffLabel Disclosure: Off label use of FLT3 inhibitors

<< Previous Presentation | Next Presentation